AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies

Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate

Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right

Pfizer drug delivers breakthrough in late-stage blood cancer trial

Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis

FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer

The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR